STOP 2G-TKI and EURO-SKI Trials of Discontinuation of Tyrosine Kinase Inhibitor Therapy for Patients with CML


STOP 2G-TKI and EURO-SKI Trials of Discontinuation of Tyrosine Kinase Inhibitor Therapy for Patients with CML
Slides from presentations at ASH 2014 and transcribed comments from a recent interview with Jorge E Cortes, MD (1/14/15)
Rea D et al. Dasatinib or nilotinib discontinuation in chronic phase (CP)-chronic myeloid leukemia (CML) patients (pts) with durably undetectable BCR-ABL transcripts: Interim analysis of the STOP 2G-TKI study with a minimum follow-up of 12 months — On behalf of the French CML group Filmc. Proc ASH 2014;Abstract 811.

Mahon FX et al. Interim analysis of a pan European stop tyrosine kinase inhibitor trial in chronic myeloid leukemia: The EURO-SKI study. Proc ASH 2014;Abstract 151.

Dr Cortes is DB Lane Cancer Research Distinguished Professor for Leukemia Research and Deputy Chairman and Section Chief of AML and CML in the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas.